COPD

The value of a patient-first approach and telehealth for addressing the complex health care coordination needs of patients with rare pulmonary diseases has never been more critical than during the COVID-19 pandemic.

Agency hopes green light for complex drug device combination improves competition and access more affordable medications.

Wixela Inhub is indicated for the treatment of asthma in patients 4 years of age and older and maintenance treatment of patients with chronic obstructive pulmonary disease.

Breo Ellipta is indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Advair Diskus is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease.

Bevespi is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Pharmacists have the potential to make a positive impact by screening patients, providing counseling, encouraging beneficial interventions, and helping tailor patient regimens based on personalized needs.

Study shows the benefit of green and blue spaces for individuals with COPD living in urban communities.

Inspiratory muscle training was originally devised to be used by athletes and individuals with breathing problems such as chronic obstructive pulmonary disease, asthma, and bronchitis.

Ten quiz questions to assess your knowledge on common treatments for chronic obstructive pulmonary disease.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Both asthma and chronic obstructive pulmonary disease cause swelling in the airways that makes it difficult to breathe.

Forced exhalation volume in one second and forced vital capacity can determine the stage severity for chronic obstructive pulmonary disease.

New drug products from Glenmark Pharmaceuticals and Cipla Limited are therapeutic equivalents to Sunovion Pharmaceuticals’ Brovana Inhalation Solution, 15 mcg/2 mL.

While the prevalence of COVID-19 in patients with COPD is relatively low, those who are infected with the virus experience more severe symptoms than those without COPD.

According to the survey results, 56% of patients with chronic obstructive pulmonary disease reported that COVID-19 has made it difficult for them to receive treatment

In the midst of the COVID-19 pandemic, it is important that individuals who are at higher risk for poor outcomes from infection with vaccine-preventable diseases remain up-to-date with their immunizations.

Pharmacists should familiarize themselves with these therapies to help patients lessen the risk of emergency department visits and hospitalizations.

In the study, more patients with allergies had chronic obstructive pulmonary disease (COPD), which is a known risk factor for severe disease with COVID-19.

They can help patients improve inhalation technique, ensuring better medication adherence.

Digital health tools were a major theme during the first-ever NASP Challenge, comprising 4 of the 5 finalists.

The triple combination therapy is the first single inhaler triple therapy approved for both asthma and COPD and is the only single inhaler triple therapy available as a once-daily inhalation.

Chronic obstructive pulmonary disease may remain undetected due to individuals thinking that the symptoms are a normal sign of aging.

Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere, AstraZeneca) has been approved by the FDA for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), according to a press release.

Although COPD often develops as a result of smoking, researchers have long puzzled over why nearly one-third of cases occur in people who never smoked.

At the first educational session of PQA, the speakers discussed pharmacists’ roles in influencing outcomes associated with social determinants of health in the US population.

During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.

Over $170 billion in health care spending is attributed to smoking.

As COPD progresses, patients can experience exacerbations leading to a decreased quality of life and increased costs.

Chronic obstructive pulmonary disease (COPD) leads in hospital costs, physician services, and prescription drugs.